Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Altimmune, Inc. (ALT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Altimmune’s common stock, par value $0.0001 per share, is registered on The Nasdaq Global Market under the symbol ALT, and its Exchange Act and Securities Act filings offer detailed insight into its clinical, financial and corporate activities.
For a late clinical-stage company focused on peptide-based therapeutics for liver, metabolic and cardiometabolic diseases, periodic reports and current reports are particularly important. Forms such as the annual report on Form 10-K and quarterly reports on Form 10-Q (when available) describe Altimmune’s business, risk factors, clinical programs and financial condition. Current reports on Form 8-K document material events, including clinical trial results for pemvidutide, Fast Track and Breakthrough Therapy designations, equity distribution agreements for at-the-market offerings, amendments to loan facilities, executive transitions and annual meeting outcomes.
Altimmune’s proxy materials, such as the definitive proxy statement on Form DEF 14A, outline governance matters, board composition, executive compensation and items submitted to stockholders at the annual meeting. These filings help investors understand how the company is overseen and how leadership is incentivized as it advances pemvidutide through Phase 2 and prepares for planned Phase 3 development in MASH.
On Stock Titan, Altimmune filings are updated in near real time as new documents are posted to EDGAR. AI-powered tools summarize lengthy filings, highlight key terms in agreements such as loan amendments or equity distribution arrangements, and make it easier to locate information on topics like clinical milestones, financing capacity or voting results. Users can also review disclosures related to capital structure, including at-the-market programs and term loan facilities, to see how Altimmune funds its liver and cardiometabolic disease pipeline.
Diane Jorkasky, a director of Altimmune, Inc. (ALT), received a grant of stock options on 09/25/2025. The Form 4 shows an award of 48,800 stock options with an exercise price of $3.92 per share and an expiration date of 09/25/2035. The options were reported as acquired and are held directly by the reporting person. The shares underlying the option vest in substantially equal monthly installments over the 12 months following the grant date, subject to continued service. The filing was signed by Gregory Weaver as Attorney-in-Fact on 09/29/2025.
Altimmune insider activity: Director John Gill reports three items: a previously made bona fide gift of 2,714 shares of common stock, a correction that he currently holds zero shares directly or indirectly, and an option award for 48,800 shares with an exercise price of $3.92. The option was granted on the reported transaction date and vests monthly over 12 months beginning after the grant, with an exercise term extending roughly ten years from the grant date. The filing clarifies prior reporting errors that overstated his direct holdings by 57 shares and documents that the shares underlying the option are exercisable upon vesting.
Altimmune, Inc. (ALT) director Klaus Schafer reported receipt of a stock option award on 09/25/2025 that grants the right to buy 48,800 shares of common stock at an exercise price of $3.92 per share. The option becomes exercisable in substantially equal monthly installments over the 12 months following the grant date, subject to continued service, and expires on 09/25/2035. Following the reported transaction, the reporting person beneficially owns 48,800 option shares directly. The filing was submitted via counsel and signed by an attorney-in-fact on 09/29/2025.
Altimmune director Mitchel Sayare was granted an option to purchase 48,800 shares of common stock at a $3.92 exercise price. The option was granted on 09/25/2025, becomes exercisable in substantially equal monthly installments over the 12 months following that date, and expires on 09/25/2035. The reporting on Form 4 indicates the position is held directly. The filing is signed by an attorney-in-fact on behalf of the reporting person.
Altimmune, Inc. director Philip Hodges was granted a stock option on 09/25/2025 to buy 48,800 shares of Altimmune common stock at an exercise price of $3.92 per share. The option becomes exercisable in substantially equal monthly installments over the 12 months following the grant date, subject to Hodges' continued service, and expires on 09/25/2035. After this grant, the reporting person beneficially owns 48,800 underlying shares on a direct basis. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Wayne Pisano, a director of Altimmune, Inc. (ALT), was granted stock options to purchase 48,800 shares of common stock at an exercise price of $3.92 per share. The options are exercisable beginning on 09/25/2025 and expire on 09/25/2035. The grant vests in substantially equal monthly installments over the 12 months following 09/25/2025, subject to continued service. Following the reported transaction, the reporting person beneficially owns 48,800 option shares, held directly.
Altimmune, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on September 25, 2025. As of the August 12, 2025 record date, 88,257,253 common shares were outstanding and entitled to vote. A total of 51,688,116 shares were present in person or by proxy, representing 58.6% of the voting power and establishing a quorum.
Stockholders elected all nominated directors, including Chairman Jerome Durso and Chief Executive Officer Vipin K. Garg, Ph.D., with each nominee receiving more votes “for” than “withheld.” Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2025, with 48,959,891 votes for, 1,355,769 against and 1,372,456 abstentions.
In an advisory “say-on-pay” vote, stockholders approved the compensation of Altimmune’s named executive officers, with 14,885,881 votes for, 6,683,682 against and 267,424 abstentions, plus 29,851,129 broker non-votes. Stockholders also approved a proposal to authorize possible adjournment of the meeting to allow additional proxy solicitation, with 33,695,815 votes for, 16,363,206 against and 1,629,095 abstentions.
Altimmune insider grant summary: Linda M. Richardson, listed as Chief Commercial Officer and a director, reported equity awards on 09/16/2025. She was awarded stock options to purchase 278,000 shares with an exercise price of $3.63 and restricted stock units representing 96,000 shares. Both awards vest over four years, with 25% vesting on September 16, 2026, and the remainder vesting in installments thereafter; the options expire September 16, 2035. Following the transaction, Richardson beneficially owns 278,000 option shares and 96,000 RSUs as reported. The filing was signed by an attorney-in-fact on 09/17/2025.
Altimmune, Inc. (ALT) Form 3: Linda M. Richardson submitted an initial Section 16 Form 3 reporting relationship to Altimmune as Chief Commercial Officer and a director-level officer. The filing states the date of the event as 09/16/2025 and the Form was signed by an attorney-in-fact on 09/17/2025. The Form explicitly notes no securities are beneficially owned by the reporting person and includes Exhibit 24 (Power of Attorney).
Altimmune, Inc. (ALT) is holding a virtual 2025 Annual Meeting of Stockholders on September 25, 2025 at 8:30 a.m. Eastern accessible at https://www.cstproxy.com/altimmune/2025 using a 12-digit control number. The proxy statement presents routine governance items: election of directors, ratification of Ernst & Young (E&Y) as independent auditors for the year ending December 31, 2025, an annual advisory "say-on-pay" vote on named executive officer compensation, and authorization to adjourn the meeting.
The filing references corporate governance materials and the Company Code of Ethics available on the investor relations site and notes the Audit Committee received PCAOB-required disclosures from E&Y and recommended inclusion of audited financial statements in the 2024 Form 10-K. Named executive officers listed for 2024 include Vipin K. Garg, Ph.D. (CEO), M. Scott Harris, M.D. (CMO), and M. Scot Roberts, Ph.D. (CSO). Benefit highlights include a 401(k) Plan with a 100% match on the first 4% of participant contributions. The statement also describes director nomination processes and related-party/merger background.